GlassScriptPhysician profile
Stephanie D Carperos
NPI 1841244910
$4,548.00
in general payments reported to CMS, 2019-2025
38 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $350 · 2021: $1,208 · 2022: $723 · 2023: $606 · 2024: $907 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,764.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $656.97 | 2020-2024 | Airsupra, Farxiga |
| Novo Nordisk INC | $514.83 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $430.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $372.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $345.22 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $226.90 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $215.53 | 2019-2022 | |
| Amgen INC. | $185.60 | 2019-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $167.59 | 2019-2021 | |
| Edwards Lifesciences Corporation | $116.04 | 2019 | |
| Pfizer INC. | $114.72 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $114.15 | 2022-2024 | Rexulti |
| Abbott Laboratories | $108.92 | 2022 | |
| Merck Sharp & Dohme LLC | $95.81 | 2020-2023 | Verquvo, Belsomra |
| Nestle Healthcare Nutrition INC. | $89.41 | 2021-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Carperos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.